ASB 17061

Drug Profile

ASB 17061

Alternative Names: ASB-17061

Latest Information Update: 27 May 2014

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Asubio Pharmaceuticals
  • Class Skin disorder therapies
  • Mechanism of Action Chymase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Atopic dermatitis

Most Recent Events

  • 27 May 2014 Discontinued - Phase-II for Atopic dermatitis in USA (PO)
  • 01 Jan 2014 Asubio Pharmaceuticals completes a phase II trial in Atopic dermatitis in USA (NCT01756898)
  • 25 Nov 2013 Asubio Pharmaceuticals completes enrolment in its phase II trial for Atopic dermatitis in USA (NCT01756898)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top